Sequential treatments in hereditary leiomyomatosis and renal cell carcinoma (HLRCC): Case report and review of the literature. [caso clínico]
Por: De Velasco, Guillermo [Oncología Médica]
| Muñoz, César [Oncología Médica] | Sepúlveda Sánchez, Juan Manuel [Oncología Médica] | Castellano, Daniel [Oncología Médica].
Colaborador(es): Servicio de Oncología Médica.
Tipo de material: 
ArtículoEditor: Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2015Descripción: 9(3-4):E243-6.Recursos en línea: Acceso libre Resumen: The overall survival for patients with advanced papillary renal carcinoma (RCC) is still limited. Although multikinase inhibitors have recently been developed for clear cell carcinoma, response rates in other histology non-clear cell RCC are poor and patients often face dose-limiting toxicities which lead to a reduction in prognosis and treatment success. We present a patient with hereditary leiomyomatosis and RCC (HLRCC), showing a sustained response for more than 12 months to gemcitabine-bevacizumab therapy after failure tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) therapies.
| Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
|---|---|---|---|---|
Caso clínico
|
PC17360 (Navegar estantería) | Disponible |
Formato Vancouver:
de Velasco G, Munoz C, Sepulveda JM, Castellano D. Sequential treatments in hereditary leiomyomatosis and renal cell carcinoma (HLRCC): Case report and review of the literature. Can Urol Assoc J. 2015 Mar-Apr;9(3-4):E243-6.
PMID: 26085897
PMC445565
Contiene 17 referencias
The overall survival for patients with advanced papillary renal carcinoma (RCC) is still limited. Although multikinase inhibitors have recently been developed for clear cell carcinoma, response rates in other histology non-clear cell RCC are poor and patients often face dose-limiting toxicities which lead to a reduction in prognosis and treatment success. We present a patient with hereditary leiomyomatosis and RCC (HLRCC), showing a sustained response for more than 12 months to gemcitabine-bevacizumab therapy after failure tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) therapies.
No hay comentarios para este ejemplar.